Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ATAI Life Sciences NV - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ATAI
Nasdaq
8731
https://atai.life/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ATAI Life Sciences NV
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
- Mar 28th, 2024 11:00 am
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
- Mar 27th, 2024 11:00 am
atai Life Sciences advances VLS-01 for treatment-resistant depression
- Mar 12th, 2024 4:35 pm
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
- Mar 4th, 2024 1:00 pm
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
- Feb 28th, 2024 10:00 pm
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
- Feb 6th, 2024 10:00 pm
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
- Jan 8th, 2024 3:15 am
Ecstasy-for-Medicine Advocate Raises $100 Million
- Jan 5th, 2024 1:54 pm
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
- Jan 4th, 2024 12:00 pm
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
- Jan 2nd, 2024 1:00 pm
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
- Nov 14th, 2023 12:03 pm
ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT
- Oct 10th, 2023 12:00 pm
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
- Oct 6th, 2023 8:05 pm
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
- Oct 2nd, 2023 8:13 pm
Insider Buying: Florian Brand Acquires 40,000 Shares of ATAI Life Sciences NV
- Sep 15th, 2023 3:02 am
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
- Sep 14th, 2023 12:02 pm
atai Life Sciences to Participate in Upcoming September Investor Conferences
- Sep 6th, 2023 8:01 pm
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
- Aug 10th, 2023 10:59 am
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
- Aug 8th, 2023 8:02 pm
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
- Jun 1st, 2023 1:10 pm
Scroll